Changing Practices in Stage I Seminoma Treatment
Author Information
Author(s): Darren R Feldman, George J Bosl
Primary Institution: Memorial Sloan-Kettering Cancer Center
Hypothesis
Should carboplatin now be offered to all patients with stage I seminoma?
Conclusion
One cycle of carboplatin is as effective and less toxic than radiation for treating stage I seminoma, but more long-term data is needed.
Supporting Evidence
- The trial showed a 5-year relapse rate of 5.3% for carboplatin and 4% for radiation.
- Carboplatin had a significantly reduced frequency of contralateral primary testicular tumors.
- Acute toxicity was generally less with carboplatin compared to radiation therapy.
- The study did not meet its primary endpoint of excluding a > 3% increase in relapse rate with carboplatin.
Takeaway
Doctors are looking at whether a single dose of a medicine called carboplatin is just as good as radiation for treating a type of testicular cancer, but they need to be careful because they don't know all the long-term effects yet.
Methodology
The study was a large phase 3 randomized trial comparing carboplatin and radiation therapy as adjuvant treatments.
Potential Biases
The study's non-inferiority design may not equate to equivalence, requiring a larger sample size.
Limitations
The median follow-up time of 6.5 years is insufficient to assess long-term toxicity.
Participant Demographics
Stage I seminoma patients, comprising up to 80% of seminomas and 40% of all testicular cancers.
Statistical Information
P-Value
1.3% increase in relapse rate
Confidence Interval
-0.7% to 3.5%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website